16/07/2007
ReGen Therapeutics Plc (London) have today announced that it has extended the scope of its licensing deal for Colostrinin™ with Metagenics Inc., its North American licensee, by amendment to the License and Supply Agreement of 13 July 2006. Colostrinin(TM) will be distributed in Australasia by Metagenics subsidiary Health World Ltd – a leading supplier of natural medicines to healthcare professionals, in these markets.
The financial terms of this deal remain commercially confidential, although it can be confirmed that all agreements with Metagenics involve the sale and supply of the Colostrinin™ active ingredient to Metagenics for them to formulate, package and market. ReGen then receives a royalty out of the sale proceeds when the formulated product is sold.
Percy Lomax, Executive Chairman of ReGen said: ‘The launch of Colostrinin™ is a validation of the Company’s work since 1998. It is the start of the Company’s commercial return from its research efforts’.
Mike Curley, Chief Science Officer of Health World, added, ‘We are very pleased to be the first company in the world to launch Colostrinin. Based on the interest shown in it by practitioners at the recent International Congress on Natural Medicine, we believe it will be an important breakthrough in helping to maintain the cognitive health of the ageing population’
Further information:
Andrew Marshall
Greycoat Communications
Tel: 020 7960 6007
Mobile: 07785 297111
Percy Lomax
Chairman and Chief Executive
ReGen Therapeutics Plc
Tel: 020 7153 4920
Imran Ahmad/Cecil Jordaan
HB Corporate
Tel: 0207 510 8600
Notes to Editors
About ReGen Therapeutics Plc
ReGen Therapeutics is a UK listed Biotech company which is developing three business lines – human and veterinary nutraceuticals, prescription pharmaceuticals for the treatment of neurodegenerative diseases and a clinical research organisation which oversees Phase I and Phase II both for ReGen and external customers. ReGen’s business strategy is to develop its nutraceutical and pharmaceutical products to a state where they can be licensed out and marketed by a third party. Its only direct sales are currently through its clinical research organisation. www.regentherapeutics.com
ReGen’s shares are traded on the AIM Market of the London Stock Exchange plc (RGT) and are quoted on the Pink Sheets of the United States over-the-counter market in the form of American Depositary Receipts (REGUY:PK).
About Metagenics, Inc.
Metagenics, Inc. is a leading developer, manufacturer and marketer of science-based nutraceuticals and medical foods sold to healthcare practitioners worldwide. The company is headquartered in San Clemente, California with manufacturing and research facilities located in Gig Harbor, Washington – including its MetaProteomics(R) Nutrigenomics Research Center and its Functional Medicine Research Center(SM) for human clinical research. Metagenics holds multiple proprietary formula patents and produces over 400 research-based products to optimize health. Metagenics demonstrates its commitment to purity and quality through its certifications for Good Manufacturing Practices (GMP) from the National Nutritional Foods Association, NSF International, and the Therapeutic Goods Administration of Australia. www.metagenics.com.
About Health World Ltd.
Health World Ltd is the leading supplier of natural medicine products to healthcare professionals in Australasia. Founded in 1985, the company is based in Brisbane Australia where it has a TGA approved GMP manufacturing facility. The company’s mission to ‘Help people live happier healthy lives ‘ is being achieved through a commitment to providing quality products, superior education and passionate service.